Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells

Oncogene. 2008 Jul 3;27(29):4075-85. doi: 10.1038/onc.2008.41. Epub 2008 Mar 3.

Abstract

In breast cancer, approximately one-third of tumors express neither the estrogen receptor (ERalpha) nor estrogen-regulated genes such as the progesterone receptor gene (PR). Our study provides new insights into the mechanism allowing hormone-activated expression of ERalpha target genes silenced in ERalpha-negative mammary tumor cells. In cell lines derived from ERalpha-negative MDA-MB231 cells, stable expression of different levels of ERalpha from a transgene did not result in transcription of PR. A quantitative comparative analysis demonstrates that inhibiting DNA methyltransferases using 5-aza-2'-deoxycytidine or specific disruption of DNMT1 by small interfering RNAs and treatment with the histone-deacetylase inhibitor trichostatin A enabled ERalpha-mediated hormone-dependent expression of endogenous PR. We show that demethylation of a CpG island located in the first exon of PR was a prerequisite for ERalpha binding to these regulatory sequences. Although not a general requirement, DNA demethylation is also necessary for derepression of a subset of ERalpha target genes involved in tumorigenesis. PR transcription did not subsist 4 days after removal of the DNA methyltransferase blocking agents, suggesting that hormone-induced expression of ERalpha target genes in ERalpha-negative tumor cells is transient. Our observations support a model where an epigenetic mark confers stable silencing by precluding ERalpha access to promoters.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Cell Line, Tumor
  • CpG Islands / genetics
  • Cytidine Monophosphate / analogs & derivatives
  • Cytidine Monophosphate / pharmacology
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors
  • DNA (Cytosine-5-)-Methyltransferases / genetics
  • DNA (Cytosine-5-)-Methyltransferases / metabolism
  • DNA Methylation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Epigenesis, Genetic / drug effects*
  • Epigenesis, Genetic / genetics
  • Estradiol / pharmacology*
  • Estrogen Receptor alpha*
  • Estrogens / pharmacology*
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Hydroxamic Acids / pharmacology
  • RNA, Small Interfering / genetics
  • Receptors, Progesterone / biosynthesis*

Substances

  • Enzyme Inhibitors
  • Estrogen Receptor alpha
  • Estrogens
  • Hydroxamic Acids
  • RNA, Small Interfering
  • Receptors, Progesterone
  • 5'-azacytidine 5'-monophosphate
  • trichostatin A
  • Estradiol
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA (Cytosine-5-)-Methyltransferases
  • DNMT1 protein, human
  • Cytidine Monophosphate